CRISPR/CAS9 genome editing: potential for human modification

Prof Paul Thomas Director, SA Genome Editing University of Adelaide, Australia South Australian Health & Medical Research Institute



Genome editing



Juliette Thomas, age 11

CRISPR genome editing

GENOME EDITING: Targeted and precise modification of any organism's genome


A revolution in biology, medicine and agriculture! (>9,000 CRISPR papers since 2012)

How could CRISPR technology be used for Human Modification?



http://en.hdbuzz.net/038

The Genome



Every cell contains the blueprint for life.....3,000,000,000 building blocks \rightarrow 20,000 genes!

Each gene has a role \rightarrow alter gene sequence or activity \rightarrow change phenotype (properties/characteristics) of an individual

Add new genes \rightarrow acquire new phenotypes

University of Adelaide

- 1. Flexible (able to target any gene/genomic region in any cell type and insert new genes into the genome)
- 2. Multiplex (able to target multiple genes simultaneously)
- 3. Permanent or temporary modification
- 4. Readily/rapidly inhibited

Does CRISPR technology tick the boxes?

CRISPR genome editing

"programmable" molecular scissors


Make a cut/modify virtually any sequence in the genome → inactivate/alter/activate any gene

CRISPR = Clustered Regularly Interspaced Short Palindromic Repeats (from bacteria)



http://en.hdbuzz.net/038

CRISPR/CAS9: Programmable genomic scissors




CAS9 = endonuclease (DNA cutting enzyme) Guide RNA = provides the "address code" for the cut


Repair of the DNA cut \rightarrow change DNA sequence \rightarrow altered gene function (or new gene added)

University of Adelaide

CRISPR in action




Vast array of genomes have been modified by CRISPR/CAS9



Hundreds of genes targeted in >50 species (including humans) \rightarrow CRISPR/Cas activity not limited by species or cell type.

CRISPR-mediated KO and transgenesis




Genome modifications using CRISPR/CAS9 include:

-KO (inactivation) → loss of fitness (disease state)

-targeted insertion of new sequences (modify endogenous gene OR add new gene (transgenesis)) → new phenotype Simultaneous inactivation of multiple genes (multiplexing)

Mutiple Gene targeting in ES cells



Many other examples...

А


One-Step Generation of Mice Carrying Mutations in Multiple Genes by CRISPR/Cas-Mediated Genome Engineering

Haoyi Wang,^{1,6} Hui Yang,^{1,6} Chikdu S. Shivalila,^{1,2,6} Meelad M. Dawlaty,¹ Albert W. Cheng,^{1,3} Feng Zhang,^{4,5} Cell (2013) and Rudolf Jaenisch^{1,3,*}

- ✓ 1. Flexible (able to target any gene/genomic region in any cell type and insert new genes into the genome)
- 2. Multiplex (able to target multiple genes simultaneously)
 - 3. Permanent or temporary modification
 - 4. Readily/rapidly inhibited

Does CRISPR technology tick the boxes?

CRISPR/CAS9 technology can be used to *transiently* activate/repress gene activity



Uses a "dead" CAS9 protein that does not cut DNA but retains gRNA binding activity

CAS9 modified to contain "Repressor" or "Transactivator" activity


 \rightarrow transient alteration of gene activity (up or down)

Does not alter DNA sequence (ie. not a permanent modification)

- ✓ 1. Flexible (able to target any gene/genomic region in any cell type and insert new genes into the genome)
- 2. Multiplex (able to target multiple genes simultaneously)
- ✓ 3. Permanent or temporary modification
 - 4. Readily/rapidly inhibited

Does CRISPR technology tick the boxes?

Inhibition of Cas9 activity using small proteins



Small protein (from phage) interferes with CAS9 activity to prevent binding at target site

May be useful for rapid inhibition of CRISPR/Cas9-induced phenotypic change

University of Adelaide

- ✓ 1. Flexible (able to target any gene/genomic region in any cell type and insert new genes into the genome)
- 2. Multiplex (able to target multiple genes simultaneously)
- ✓ 3. Permanent or temporary modification
- 4. Readily/rapidly inhibited

Does CRISPR technology tick the boxes?

Yes, promising technology, but there are issues...

Barriers to use of CRISPR technology for human modification (in 2040)

Societal – Ethics of CRISPR modification (designer babies, defense)

Safety – Unintended consequences, off-target modifications/binding


 Technical -Delivery to target site (major issue)
-Efficiency of generating modification (particularly inserting genes)
-limitations of PAM requirement (disappearing)

Biological -what genes should be modified or inserted to generate the intended phenotype (vision/muscle function/metabolism) -crossing the blood brain barrier

We can expect progress in all of the above...

Using CRISPR/Cas9 for gene therapy

Use CRISPR gene editing to *correct* a disease-causing mutation (human modification)



Actively developed for a host of genetic diseases of the: -liver -eye -muscle -blood -and others...

We have CSIRO/UA/SAHMRI Synthetic Biology Fellowship for development of DMD CRISPR therapy

Acknowledgements







Thomas lab

James Hughes **Fatwa Adikusuma** Ella Thomson Ruby Moffat Chandran Pfitzner Connor Larson Stefka Tasheva Louise Robertson

SA Genome Editing

Sandie Piltz Melissa White

Funding

USA Defense Advanced Research Projects Agency (DARPA)

National Health and Medical Research Council (NHMRC)

CSIRO (Synthetic Biology Future Science Fellowship)

Australian Phenomics Network